Company intelligence / Profile preview

OWL Global

Ownership: Private
Development stage: Other

Overview

Owl Therapeutics has a diversified pipeline targeting brain health through supercharged microglia. Its lead asset OWL‑1410 is entering Phase 2 trials for moderate/severe TBI, supported by promising early clinical data. The company leverages generative AI to design novel drugs and partners with Gryphon Bio to develop diagnostic blood tests that improve trial success rates. Additional programs target related CNS indications including Alzheimer’s disease, post-traumatic epilepsy, and post-traumatic headache. Several earlier assets have been discontinued or are preclinical.

Therapeutic areas: Neurology
Modalities: Small moleculeLarge molecule
Industry: Biotech

Partnerships

Gryphon Bio (diagnostic biomarkers/blood tests)Abliva AB (NeuroSTAT licensing/development partnership)

Beyond the preview

Go deeper on OWL Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OWL Global.

Explore the full profile